Kiniksa Pharmaceuticals, Ltd.
KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatoā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$46.74
Price+1.26%
$0.58
1Y
Price
Market Cap
$3.468b
Mid
Price/Earnings 3y Avg5y Avg
62.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+15.2%
EBITDA Margin+10.2%
Net Profit Margin+18.3%
Free Cash Flow Margin+15.2%
EBITDA Margin+10.2%
Net Profit Margin+18.3%
Free Cash Flow MarginRevenue
$677.564m
+41.3%
1y CAGR+40.2%
3y CAGR+148.0%
5y CAGREarnings
$59.005m
+183.2%
1y CAGR-105.3%
3y CAGR-24.9%
5y CAGREPS
$0.75
+175.0%
1y CAGR-105.8%
3y CAGR-26.1%
5y CAGRBook Value
$567.606m
$763.633m
Assets$196.027m
Liabilities$9.497m
DebtDebt to Assets
1.2%
0.2x
Debt to EBITDAFree Cash Flow
$25.412m
+300.3%
1y CAGR+174.8%
3y CAGR+157.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company